Clinical Trials in New York State

Showing 3561-3580 of 8,190 trials

Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis

NCT03970733

In the Main Study Phase a total of 246 subjects were randomized 2:2:1 into three treatment groups to receive either VLA15 with Alum (lower or higher dose) or Placebo. Main Study Phase vaccinations were administered as intramuscular injections on Day 1, Day 57 and Day 180. In the Booster Phase subjects from the higher dose group who completed their primary immunization schedule according to protocol will be randomized 2:1 to receive an additional higher dose VLA15 vaccination or Placebo at Month 18. Study duration in the Main Study Phase per subject is a maximum of 20 months. Overall study Duration is estimated to be 22 months. Study duration per subject in the Booster Phase is a maximum of approximately 13 months. Study duration per subject in the Main Study Phase and Booster Phase together is estimated to be a maximum of approximately 33 months. Overall study duration (i.e., First-Subject-In to Last-Subject Out/ end of Booster Phase) is estimated to be approximately 37 months.

Lyme Borreliosis

Pfizer246 participantsStarted Jul 2019

Milford, Connecticut, United States • Stamford, Connecticut, United States • Binghamton, New York, United States +2 more locations

COMPLETED51 miles

Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States

NCT02993120

This is a multicenter observational cohort study with both retrospective and prospective data collection components in subjects with ASCVD. The purpose of this study is to better understand cholesterol treatment patterns in the context of a changing landscape in subjects with ASCVD.

Medical Conditions to be StudiedDyslipidemiaASCVD Management

Amgen5,006 participantsStarted Dec 2016

Chandler, Arizona, United States • Glendale, Arizona, United States • Tucson, Arizona, United States +115 more locations

Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis

Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States

Find Trials by Condition in New York State

Evaluation of a Daily Disposable Silicone Hydrogel Multifocal Contact Lens in Myopes and Hyperopes

PerQseal® Impella Early Feasibility Study

VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study

Safety Study of SEA-CD40 in Cancer Patients

A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

ID & Testing in Male Partners

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

Rapid Diagnostics for HIV and Hepatitis

A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer

ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

Relative Bioavailability of LY03010 Compared to Listed Drug

Thrombosomes® in Bleeding Thrombocytopenic Patients

A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults

Trauma Informed Intervention to Support Engagement in HIV Care Among MSM (THRIVE+)

Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)